Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer‐blinded head‐to‐head trial
G. Holzer,M. Hoke,S. Sabeti‐Sandor,T. Perkmann,A. Rauscher,B. Strassegger,S. Radakovic,A. Tanew
DOI: https://doi.org/10.1111/jdv.16635
2020-07-02
Journal of the European Academy of Dermatology and Venereology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The effect of adalimumab and fumaric acid esters (FAE) on the cardiovascular risk associated with psoriasis has only been investigated scarcely in randomized controlled studies.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>The aim of this prospective, randomized controlled head‐to‐head trial was to compare the influence of adalimumab and FAE on cardiovascular disease markers in psoriasis patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>65 patients with moderate to severe plaque psoriasis were randomly assigned to adalimumab or FAE treatment for 6 months. Cardiovascular hemodynamic parameters (flow mediated dilation (FMD), nitro‐glycerine mediated dilation (NMD) and carotid intima media thickness (CIMT), blood pressure) were assessed at baseline(v0) and after 6 months(v6). Cutaneous disease severity, inflammatory and lipid cardiovascular risk markers were analysed at baseline(v0), after three(v3) and six months(v6).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>After 6 months of treatment FMD in the adalimumab group increased significantly (v0 5,9% (6,4% S.D), v6 8,0% (4,8% S.D.), p=0,048) but not in the FAE group. (v0 7,0% (4,1% S.D), v6 8,4% (6,1% S.D.), p=0,753) This was paralleled by a significant decrease of hsCRP in the adalimumab group in comparison to the FAE group (v0: 0,39 mg/dl (0,38 S.D.), v6: 0,39mg/dl (0,48 S.D.), p=0,043). No significant changes were observed in any other hemodynamic parameters. FAE, however, additionally decreased total cholesterol (p=0,046) and apolipoprotein B (p=0,041) levels compared to adalimumab. Mean PASI (psoriasis area severity score) reduction was greater but not significant (p=0,116) under adalimumab treatment compared to FAE treatment ( ‐71,1% (29,9 S.D) vs. ‐54,6% (45,7%)).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>In our study both treatments were documented to exert effects on the cardiovascular system. While adalimumab showed anti‐inflammatory effects and improved FMD, FAE interacted favourably with the cholesterol metabolism.</p></section>
dermatology